Skip to main content
. Author manuscript; available in PMC: 2021 Dec 15.
Published in final edited form as: Cancer Res. 2021 Feb 1;81(12):3255–3269. doi: 10.1158/0008-5472.CAN-20-3892

Figure 6. EphrinB2 is released into patient plasma and mouse plasma after high dose RT to PDAC tumors.

Figure 6.

A. ELISA for ephrinB2 in patient plasma samples collected from patients with LAPC, prior to, during, and after treatment with SBRT. X axis shows dose per fraction of SBRT, patients were treated with 3 fractions. Y axis represents ephrinB2 plasma concentration determined by standard curve. *p<0.05 B. ELISA for ephrinB2 in mouse plasma collected 2 weeks following increasing single fraction doses of RT to flank grafts, Y axis represents absorbance at 450nm minus negative control. N=6 replicates. C. ELISA for ephrinB2 in mice implanted with WT KPC flank grafts, vs. ADAM10 KO KPC grafts, Y axis represents absorbance at 450nm minus negative control N=6 replicates. P values calculated using Student’s T-Test.